Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma

Journal of Pathology

Volumn 182, Issue 2, 1997, Pages 211-216

  Kumar Singh, Samir ^a,b   Vermeulen, Peter B ^a,b   Weyler, Joost ^a   Segers, Kurt ^a,b   Weyn, Barbara ^a   Van Daele, Andre ^a   Dirix, Luc Y ^a,b   Van Oosterom, Allan T ^a,b   Van Marck, Eric ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Angiogenesis Group   (Belgium)

Author keywords

Angiogenesis; Computerized image analysis; Malignant mesothelioma; Prognosis

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN;

ADULT; ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS;

ANTIGENS, CD31; ANTIGENS, CD34; FEMALE; GENE EXPRESSION; GENES, P53; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PLEURAL NEOPLASMS; PROGNOSIS;

EID: 0030835752     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D     Document Type: Article

References (30)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? (Editorial). J Natl Cancer Inst 1990; 82: 4-6.
2. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991; 64: 327-336.
3. Friesel RE, Maciag T. Molecular mechanism of angiogenesis: fibroblast growth factor signal transduction. FASEB J 1995; 9: 919-925.
4. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039.
5. Folkman J. Tumor angiogenesis and tissue factor (Comment). Nat Med 1996; 2: 167-168.
6. Gasparini G, Harris AL. Clinical importance of the determination of tumour angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995; 13: 765-782.
7. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
8. Vermeulen PB, Verhoeven D, Fierens H, et al. Microvessel quantification in primary colorectal carcinoma: an immunohistochemical study. Br J Cancer 1995; 71: 340-343.
9. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61.
10. Vermeulen PB, Roland L, Mertens V, et al. Correlation of intratumoural microvessel density and p53 protein expression in human colorectal adenocarcinoma. Microvascular Res 1996; 51: 164-174.
11. Henderson DW, Shilkin KB, Langlois SLP, Whitaker D (eds). Malignant Mesothelioma. New York: Hemisphere, 1992.
12. Branchaud RM, MacDonald JL, Kane AB. Induction of angiogenesis by intraperitoneal injection of asbestos fibres. FASEB J 1989; 3: 1747-1752.
13. Vermeulen PB, Dirix LY, Martin M, et al. Serum levels of b-FGF and VEGF in patients with metastatic solid tumours. Proc ASCO 15: 90(26).
14. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, et al. Patho-and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model. Cancer Immunol Immunother 1994; 39: 347-359.
15. Monti G, Jaurand MC, Monnet I, et al. Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment. Cancer Res 1994; 54: 4419-4423.
16. Schmitter D, Lauber B, Fagg B, Stahel HA. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer 1992; 51: 296-301.
17. Antony VB, Hott JW, Godbey SW, Holm K. Angiogenesis in mesotheliomas. Role of mesothelial cell derived IL-8. Chest 1996; 109: 21S-22S.
18. Kumar-Singh S, Segers K, Rodeck U, et al. WT1 mutations in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell type transition, and prognosis. J Pathol (in press).
19. Segers K, Backhovens H, Singh SK, et al. Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma. Virchows Arch 1995; 427: 431-436.
20. Coltelli P, Gualtieri P. Colour techniques in digital microscopy. Eur Microsc Anal. 1994; 31: 25-27.
21. Goulding H, Abdul Rashid NF, Robertson JF, et al. Assessment of angiogenesis in breast carcinoma: an important factor in prognosis? [see comments]. Hum Pathol 1995; 26: 1196-1200.
22. Ramael M, Jacobs W, Weyler J, et al. Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA). J Pathol 1994; 172: 247-253.
23. Bethwaite PB, Delahunt B, Holloway LJ, Thornton A. Comparison of silver-staining nucleolar organizer region (AgNOR) counts and proliferating cell nuclear antigen (PCNA) expression in reactive mesothelial hyperplasia and malignant mesothelioma. Pathology 1995; 27: 1-4.
24. Lee TC, Zhang Y, Aston C, et al. Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. Cancer Res 1993; 53: 2858-2864.
25. Langerak AW, De Laat PAJM, Van Der Linden-Van Beurden CAJ, et al. Expression of platelet derived growth factor and receptors in human malignant mesothelioma in vitro and in vivo. J Pathol 1996; 178: 151-160.
26. Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth factor, platelet-derived growth factor, insulin like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol 1994; 145: 1023-1029.
27. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994; 9: 963-969.
28. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-1584.
29. Walz R, Koch HK. Malignant pleural mesothelioma: some aspects of epidemiology, differential diagnosis and prognosis. Histological and immunohistochemical evaluation and follow-up of mesotheliomas diagnosed from 1964 to January 1985. Pathol Res Pract 1990; 186: 124-134.
30. Mark EJ, Shin DH. Diffuse malignant mesothelioma of the pleura: a clinicopathological study of six patients with a prolonged symptom-free interval or extended survival after biopsy and a review of the literature of long-term survival. Virchows, Arth A [Pathol Anat Histopathol] 1993; 422: 445-451.